Skip to main content
. Author manuscript; available in PMC: 2024 Jul 22.
Published in final edited form as: Vaccine. 2022 Nov 1;40(50):7176–7181. doi: 10.1016/j.vaccine.2022.10.031

Fig. 3. Median increased vaccine impact of improved vaccines compared to a vaccine with 30% efficacy and 2-year duration, assuming either low (20%) or high (50%) coverage and assuming a baseline NG prevalence of 1.125% in women and 0.75% in men.

Fig. 3.

“Increased vaccine impact” is calculated as the ratio of the reduction in prevalence in the improved vaccine compared to the reduction in prevalence of the vaccine with 30% efficacy and 2-year duration of protection.